Patents by Inventor Gunnar Aberg

Gunnar Aberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • S-Isomer of 2- piperidine and Other Dermal Anesthetic Agents
    Publication number: 20100179114
    Abstract: The present invention relates to the S-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep.
    Type: Application
    Filed: March 4, 2010
    Publication date: July 15, 2010
    Applicant: BRIDGE PHARMA, INC.
    Inventors: Gunnar Aberg, Jan L. Chen
  • OCULAR FORMULATIONS OF NORKETOTIFEN
    Publication number: 20100130550
    Abstract: Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen.
    Type: Application
    Filed: November 20, 2009
    Publication date: May 27, 2010
    Applicant: BRIDGE PHARMA, INC.
    Inventors: A.K. Gunnar Aberg, Keith Johnson
  • Use of RR/SR-ractopamine
    Patent number: 7723392
    Abstract: A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: May 25, 2010
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, Karl Reuter, Viktor Meier, Florian Stolz, Eliso Gogritchiani
  • Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
    Patent number: 7718674
    Abstract: The present invention relates to the S-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: May 18, 2010
    Assignee: Bridge Pharma, Inc.
    Inventor: Gunnar Aberg
  • Treatment xerophthalmia with norketotifen
    Publication number: 20100105734
    Abstract: Methods of using a cycloheptathiophene compound for the treatment of xerophthalmia are described, as are formulations and compositions for such treatment.
    Type: Application
    Filed: December 24, 2008
    Publication date: April 29, 2010
    Inventors: A.K. Gunnar Aberg, Keith Johnson
  • DERMAL COMPOSITIONS OF SUBSTITUTED AMIDES AND THE USE THEREOF AS MEDICATION FOR PAIN AND PRURITUS
    Publication number: 20100041704
    Abstract: Dermal compositions comprising topical formulations of bupivacaine or ropivacaine, characterized by effective dermal absorption and long duration of dermal anesthetic activity, and intended for use in patients suffering from pruritus and dermal pain, including neuropathic pain, are provided. Compositions containing both bupivacaine and capsaicin are provided. Methods of alleviating pain by the topically administration of these compounds are also provided.
    Type: Application
    Filed: January 11, 2008
    Publication date: February 18, 2010
    Inventors: A.K. Gunnar Aberg, Keith A. Johnson
  • Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain
    Patent number: 7592458
    Abstract: The present invention relates to new tetralin compounds, the methods of preparing said tetralin compounds, the method of using said tetralin compounds as local anesthetics and dermal anesthetics, said compounds having particularly valuable properties as dermal and topical anesthetics in mammals, including man, as well as compositions containing said compounds.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: September 22, 2009
    Inventors: George E. Wright, A. K. Gunnar Aberg
  • Optically active isomers of ketotifen and therapeutically active metabolites thereof
    Patent number: 7557128
    Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: July 7, 2009
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
  • Optically active isomers of ketotifen and therapeutically active metabolites thereof
    Publication number: 20090149502
    Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.
    Type: Application
    Filed: February 12, 2009
    Publication date: June 11, 2009
    Inventors: A. K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
  • Use of RR/SR-ractopamine
    Publication number: 20090143480
    Abstract: A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.
    Type: Application
    Filed: August 6, 2008
    Publication date: June 4, 2009
    Inventors: A.K. Gunnar Aberg, Karl Reuter, Viktor Meier, Florian Stolz, Eliso Gogritchiani
  • Formulations of Indanylamines and the Use Thereof as Local Anesthetics and as Medication for Chronic Pain
    Publication number: 20090137628
    Abstract: Dermal and mucosal formulations of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine, characterized by rapid dermal and mucosal absorption and long duration of therapeutic activity are provided. Also provided are solutions of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine for injection, characterized by short onset time and long duration of activity. Formulations containing both 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine and capsaicin are also provided.
    Type: Application
    Filed: September 22, 2006
    Publication date: May 28, 2009
    Applicant: BRIDGE PHARMA, INC.
    Inventors: A.K. Gunnar Aberg, Keith Johnson
  • Synergisms between repartitioning and immunomodulating compounds
    Publication number: 20090054338
    Abstract: Combination therapies of adrenergic beta-receptor agonists and beta-glucans are described.
    Type: Application
    Filed: August 6, 2008
    Publication date: February 26, 2009
    Inventor: A.K. Gunnar Aberg
  • Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals
    Publication number: 20090004235
    Abstract: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal.
    Type: Application
    Filed: November 19, 2007
    Publication date: January 1, 2009
    Inventor: A.K. Gunnar Aberg
  • Optically active isomers of ketotifen and therapeutically active metabolites thereof
    Publication number: 20080287498
    Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.
    Type: Application
    Filed: April 30, 2007
    Publication date: November 20, 2008
    Inventors: A.K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
  • METHODS AND COMPOSITIONS FOR TREATING PULMONARY DISORDERS USING OPTICALLY PURE (R,R)-FORMOTEROL
    Publication number: 20080161411
    Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
    Type: Application
    Filed: March 13, 2008
    Publication date: July 3, 2008
    Applicant: SEPRACOR INC.
    Inventors: Gunnar ABERG, John MORLEY
  • Methods for treating urinary incontinence in patients suffering from memory disorders
    Patent number: 7390816
    Abstract: Methods are disclosed using trospium, an antimuscarinic smooth muscle relaxant, for the treatment of smooth muscle disorders, while avoiding the concomitant liability of adverse side effects associated with conventional antimuscarinic treatment.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: June 24, 2008
    Assignee: Bridge Pharma, Inc.
    Inventor: A.K. Gunnar Aberg
  • Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
    Patent number: 7368120
    Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
    Type: Grant
    Filed: January 31, 2005
    Date of Patent: May 6, 2008
    Assignee: Sepracor Inc.
    Inventors: Gunnar Aberg, John Morley
  • Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals
    Publication number: 20070282010
    Abstract: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal.
    Type: Application
    Filed: May 30, 2007
    Publication date: December 6, 2007
    Applicant: BRIDGE PHARMA, INC.
    Inventor: A.K. Gunnar Aberg
  • Optically active isomers of ketotifen and therapeutically active metabolites thereof
    Patent number: 7226934
    Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen.
    Type: Grant
    Filed: September 12, 2000
    Date of Patent: June 5, 2007
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
  • Compositions of descarboethoxyloratadine
    Patent number: 7214683
    Abstract: Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
    Type: Grant
    Filed: March 16, 1998
    Date of Patent: May 8, 2007
    Assignee: Sepracor Inc.
    Inventors: A. K. Gunnar Aberg, John R. McCullough, Emil R. Smith